Lise Jodaitis, Noémie Ligot, Rudy Chapusette, Thomas Bonnet, Nicolas Gaspard, Gilles Naeije
{"title":"急性脑卒中管理滴-船模型中的大脑中动脉高密度征象。","authors":"Lise Jodaitis, Noémie Ligot, Rudy Chapusette, Thomas Bonnet, Nicolas Gaspard, Gilles Naeije","doi":"10.1159/000506971","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Large vessel occlusion (LVO) leads to debilitating stroke and responds modestly to recombinant tissue plasminogen activator (rt-TPA). Early thrombectomy improves functional outcomes in selected patients with proximal occlusion but it is not available in all medical facilities. The best imaging modality for triage in an acute stroke setting in drip-and-ship models is still the subject of debate.</p><p><strong>Objectives: </strong>We aimed to assess the diagnostic value of millimeter-sliced noncontrast computed tomography (NCCT) hyperdense middle cerebral artery sign (HMCAS) in itself or associated with clinical data for early detection of LVO in drip-and-ship models of acute stroke management.</p><p><strong>Methods: </strong>NCCT of patients admitted to the Erasme Hospital, ULB, Brussels, Belgium, for suspicion of acute ischemic stroke between January 1 and July 31, 2017, were collected. Patients with brain hemorrhages were excluded, leading to 122 cases. The presence of HMCAS on NCCT was determined via visual assessment by 6 raters blinded to all other data. An independent rater assessed the presence of LVO on digital subtraction angiography imaging or contrast-enhanced CT angiography (CTA). The sensitivity, false-positive rate (FPR), and accuracy of HMCAS and the dot sign to detect LVO were calculated. The interobserver agreement of HMCAS was assessed using Gwet's AC1 coefficient. Then, on a separate occasion, the first 2 observers rereviewed all NCCT provided with clinical clues. The sensitivity, FPR, and accuracy of HMCAS were recalculated.</p><p><strong>Results: </strong>HMCAS was found in 21% of the cases and a dot sign was found in 9%. The mean HMCAS sensitivity was 62% (95% CI 45-79%) and its accuracy was 86% (95% CI 79-92%) for detecting LVO. The interobserver reliability coefficient was 80% for HMCAS. Combined with clinical information, HMCAS sensitivity increased to 81% (95% CI 68-94; p = 0.041) and accuracy increased to 91% (95% CI 86-96%).</p><p><strong>Conclusion: </strong>When clinical data are provided, detection of HMCAS on thinly sliced NCCT could be enough to decide on transfer for thrombectomy in drip-and-ship models of acute stroke management, especially in situations where CTA is less available and referral centers for thrombectomy fewer and further apart.</p>","PeriodicalId":45709,"journal":{"name":"Cerebrovascular Diseases Extra","volume":"10 1","pages":"36-43"},"PeriodicalIF":2.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000506971","citationCount":"7","resultStr":"{\"title\":\"The Hyperdense Middle Cerebral Artery Sign in Drip-and-Ship Models of Acute Stroke Management.\",\"authors\":\"Lise Jodaitis, Noémie Ligot, Rudy Chapusette, Thomas Bonnet, Nicolas Gaspard, Gilles Naeije\",\"doi\":\"10.1159/000506971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Large vessel occlusion (LVO) leads to debilitating stroke and responds modestly to recombinant tissue plasminogen activator (rt-TPA). Early thrombectomy improves functional outcomes in selected patients with proximal occlusion but it is not available in all medical facilities. The best imaging modality for triage in an acute stroke setting in drip-and-ship models is still the subject of debate.</p><p><strong>Objectives: </strong>We aimed to assess the diagnostic value of millimeter-sliced noncontrast computed tomography (NCCT) hyperdense middle cerebral artery sign (HMCAS) in itself or associated with clinical data for early detection of LVO in drip-and-ship models of acute stroke management.</p><p><strong>Methods: </strong>NCCT of patients admitted to the Erasme Hospital, ULB, Brussels, Belgium, for suspicion of acute ischemic stroke between January 1 and July 31, 2017, were collected. Patients with brain hemorrhages were excluded, leading to 122 cases. The presence of HMCAS on NCCT was determined via visual assessment by 6 raters blinded to all other data. An independent rater assessed the presence of LVO on digital subtraction angiography imaging or contrast-enhanced CT angiography (CTA). The sensitivity, false-positive rate (FPR), and accuracy of HMCAS and the dot sign to detect LVO were calculated. The interobserver agreement of HMCAS was assessed using Gwet's AC1 coefficient. Then, on a separate occasion, the first 2 observers rereviewed all NCCT provided with clinical clues. The sensitivity, FPR, and accuracy of HMCAS were recalculated.</p><p><strong>Results: </strong>HMCAS was found in 21% of the cases and a dot sign was found in 9%. The mean HMCAS sensitivity was 62% (95% CI 45-79%) and its accuracy was 86% (95% CI 79-92%) for detecting LVO. The interobserver reliability coefficient was 80% for HMCAS. Combined with clinical information, HMCAS sensitivity increased to 81% (95% CI 68-94; p = 0.041) and accuracy increased to 91% (95% CI 86-96%).</p><p><strong>Conclusion: </strong>When clinical data are provided, detection of HMCAS on thinly sliced NCCT could be enough to decide on transfer for thrombectomy in drip-and-ship models of acute stroke management, especially in situations where CTA is less available and referral centers for thrombectomy fewer and further apart.</p>\",\"PeriodicalId\":45709,\"journal\":{\"name\":\"Cerebrovascular Diseases Extra\",\"volume\":\"10 1\",\"pages\":\"36-43\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2020-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000506971\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cerebrovascular Diseases Extra\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000506971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/4/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cerebrovascular Diseases Extra","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000506971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/4/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 7
摘要
背景:大血管闭塞(LVO)导致衰弱性卒中,对重组组织型纤溶酶原激活剂(rt-TPA)反应温和。早期取栓可改善近端闭塞患者的功能预后,但并非所有医疗机构均可采用。在急性脑卒中的情况下,滴-船模型的最佳成像方式仍然是争论的主题。目的:我们旨在评估毫米切片非对比计算机断层扫描(NCCT)高密度大脑中动脉征象(HMCAS)本身或与临床数据相关的诊断价值,以早期检测急性卒中管理滴-船模型中的LVO。方法:收集2017年1月1日至7月31日比利时布鲁塞尔Erasme医院疑似急性缺血性脑卒中患者的NCCT。排除脑出血患者,共122例。HMCAS在NCCT上的存在是通过6名评分者对所有其他数据不知情的视觉评估来确定的。独立评估者在数字减影血管造影或对比增强CT血管造影(CTA)上评估LVO的存在。计算HMCAS和点标记检测LVO的灵敏度、假阳性率(FPR)和准确性。采用Gwet的AC1系数评估HMCAS的观察者间一致性。然后,在一个单独的场合,前2名观察员回顾了所有提供临床线索的NCCT。重新计算HMCAS的灵敏度、FPR和准确性。结果:HMCAS占21%,点状征占9%。HMCAS检测LVO的平均灵敏度为62% (95% CI 45-79%),准确率为86% (95% CI 79-92%)。HMCAS的观察者间信度系数为80%。结合临床信息,HMCAS敏感性增加至81% (95% CI 68-94;p = 0.041),准确率提高到91% (95% CI 86-96%)。结论:在提供临床数据的情况下,检测薄切片NCCT上的HMCAS足以决定急性脑卒中治疗滴-船模型中是否转移取栓,特别是在CTA可用性较差、取栓转诊中心较少且距离较远的情况下。
The Hyperdense Middle Cerebral Artery Sign in Drip-and-Ship Models of Acute Stroke Management.
Background: Large vessel occlusion (LVO) leads to debilitating stroke and responds modestly to recombinant tissue plasminogen activator (rt-TPA). Early thrombectomy improves functional outcomes in selected patients with proximal occlusion but it is not available in all medical facilities. The best imaging modality for triage in an acute stroke setting in drip-and-ship models is still the subject of debate.
Objectives: We aimed to assess the diagnostic value of millimeter-sliced noncontrast computed tomography (NCCT) hyperdense middle cerebral artery sign (HMCAS) in itself or associated with clinical data for early detection of LVO in drip-and-ship models of acute stroke management.
Methods: NCCT of patients admitted to the Erasme Hospital, ULB, Brussels, Belgium, for suspicion of acute ischemic stroke between January 1 and July 31, 2017, were collected. Patients with brain hemorrhages were excluded, leading to 122 cases. The presence of HMCAS on NCCT was determined via visual assessment by 6 raters blinded to all other data. An independent rater assessed the presence of LVO on digital subtraction angiography imaging or contrast-enhanced CT angiography (CTA). The sensitivity, false-positive rate (FPR), and accuracy of HMCAS and the dot sign to detect LVO were calculated. The interobserver agreement of HMCAS was assessed using Gwet's AC1 coefficient. Then, on a separate occasion, the first 2 observers rereviewed all NCCT provided with clinical clues. The sensitivity, FPR, and accuracy of HMCAS were recalculated.
Results: HMCAS was found in 21% of the cases and a dot sign was found in 9%. The mean HMCAS sensitivity was 62% (95% CI 45-79%) and its accuracy was 86% (95% CI 79-92%) for detecting LVO. The interobserver reliability coefficient was 80% for HMCAS. Combined with clinical information, HMCAS sensitivity increased to 81% (95% CI 68-94; p = 0.041) and accuracy increased to 91% (95% CI 86-96%).
Conclusion: When clinical data are provided, detection of HMCAS on thinly sliced NCCT could be enough to decide on transfer for thrombectomy in drip-and-ship models of acute stroke management, especially in situations where CTA is less available and referral centers for thrombectomy fewer and further apart.
期刊介绍:
This open access and online-only journal publishes original articles covering the entire spectrum of stroke and cerebrovascular research, drawing from a variety of specialties such as neurology, internal medicine, surgery, radiology, epidemiology, cardiology, hematology, psychology and rehabilitation. Offering an international forum, it meets the growing need for sophisticated, up-to-date scientific information on clinical data, diagnostic testing, and therapeutic issues. The journal publishes original contributions, reviews of selected topics as well as clinical investigative studies. All aspects related to clinical advances are considered, while purely experimental work appears only if directly relevant to clinical issues. Cerebrovascular Diseases Extra provides additional contents based on reviewed and accepted submissions to the main journal Cerebrovascular Diseases.